Entity

Time filter

Source Type


Seki N.,Clinical Research Center | Matsumoto T.,Social Insurance Funabashi Central Hospital | Fukazawa M.,Social Insurance Funabashi Central Hospital
Hormone and Metabolic Research | Year: 2015

The aim of the study was to examine the relationship between the brain natriuretic peptide (BNP) level and progression or remission of diabetic nephropathy with microalbuminuria for 3 years. The subjects were 100 Japanese type 2 diabetes mellitus outpatients with microalbuminuria. Associations between metabolic parameters at baseline [HbA1c, systolic blood pressure (SBP), urine albumin-creatinine ratio (ACR), estimated glomerular filtration rate (eGFR), and BNP] and the progression or remission of diabetic nephropathy were examined for 3 years. A total of 83 patients were examined at the end of the 3-year period, including 17 with remission to normoalbuminuria, 47 with continuing microalbuminuria, and 19 with progression to macroalbuminuria. HbA1c, ACR, and BNP differed significantly among the 3 groups (p=0.024, p<0.001, p=0.002, respectively). Among baseline factors, HbA1c and BNP were significant predictors of the percentage increase in ACR for 3 years in multiple linear regression analysis (β=0.259, p=0.02; β=0.299, p=0.007, respectively). In multivariate logistic regression analysis, HbA1c and ACR were independently associated with progression of diabetic nephropathy (p=0.008, p=0.023, respectively), and ACR and BNP were independently associated with remission of diabetic nephropathy (p=0.029, p=0.012, respectively). ROC curve analysis gave a cutoff value for BNP of 14.9 pg/ml for prediction of remission of diabetic nephropathy (p=0.016). The BNP level has a relationship with diabetic nephropathy and a low BNP level predicts remission of diabetic nephropathy. Therefore, monitoring of BNP can play an important role in management of diabetic nephropathy. © Georg Thieme Verlag KG Stuttgart, New York. Source


Kamiya N.,Toho University | Suzuki H.,Toho University | Ueda T.,Chiba Cancer Center | Sato N.,National Hospital Organization Chiba Medical Center | And 11 more authors.
International Journal of Clinical Oncology | Year: 2014

Background: The aim of this study was to retrospectively investigate clinical outcomes by relative dose and dose intensity of docetaxel (DOC) as chemotherapy for Japanese patients with castration-resistant prostate cancer (CRPC). Methods: A total of 145 CRPC patients who received more than 4 courses of DOC chemotherapy at 14 hospitals between 2005 and 2011 were enrolled. Patients were divided into two groups - those receiving a higher or lower dose (mg/m2) or dose intensity (mg/m2/week). Differences between the groups regarding treatment outcomes and adverse events (AEs) were determined. Additionally, prognostic factors predictive of cancer-specific survival (CSS) in these patients were identified by both univariate and multivariate analysis. Results: The total patient group underwent a mean of 11.2 ± 7.4 DOC cycles, and the mean CSS after therapy was 15.6 ± 10.1 months. The higher-dose group had a better prostate-specific antigen (PSA) response than the lower-dose group. However, there was no significant difference between the groups in prognosis after DOC chemotherapy. Leukopenia and neutropenia were observed more frequently in the higher-dose group. Serum biomarkers (including PSA, lactate dehydrogenase and alkaline phosphatase), hemoglobin levels and presence of pain at initiation of chemotherapy, as well as the PSA nadir level on first-line hormone therapy, all were significant predictors of CSS. Conclusions: In the Japanese population, relatively low-dose DOC chemotherapy had no deleterious effect on the CSS of CRPC patients, and a lower incidence of AEs occurred, in spite of a diminished PSA response compared with those receiving a higher dose. © 2013 Japan Society of Clinical Oncology. Source


Kanda T.,Chiba University | Imazeki F.,Chiba University | Mikami S.,Kikkoman Hospital | Kato K.,Red Cross | And 13 more authors.
Oncology | Year: 2011

Advanced chronic hepatitis C patients with sustained virolological response by antivirals remain at risk for hepatocellular carcinoma (HCC). We investigated the incidence of HCC during and immediately after peginterferon-alfa-2a and ribavirin (RBV) treatment in patients with chronic hepatitis C in Japan. HCC was detected in 8 of 238 patients during and after these treatments (mean follow-up period: 572 ± 252 days). In conclusion, occurrence of HCC is not a rare event during and immediately after peginterferon-alfa-2a plus RBV treatment. In cases with cirrhosis, higher α-fetoprotein levels, old age, or a previous history of HCC treatment, clinicians should be especially alert for the possible development of HCC during and immediately after peginterferon-alfa-2a and RBV treatment. Clinicians should regularly check for the possible development of HCC even in chronic hepatitis C patients under treatment. Copyright © 2011 S. Karger AG, Basel. Source


Seki N.,Clinical Research Center | Nishimura M.,Clinical Research Center | Matsumoto T.,Social Insurance Funabashi Central Hospital | Fukazawa M.,Social Insurance Funabashi Central Hospital | Kenmochi T.,Clinical Research Center
Journal of Diabetes and its Complications | Year: 2013

Aims: We examined the relationship between the brain natriuretic peptide (BNP) level and renal function in diabetic nephropathy with microalbuminuria. Methods: The subjects were 97 Japanese type 2 diabetes mellitus outpatients with microalbuminuria. Associations between the annual rate of decline in estimated glomerular filtration rate (eGFR) and various metabolic parameters at baseline (BMI, systolic blood pressure, HbA1c, LDL cholesterol, urine albumin-creatinine ratio, BNP and eGFR) were examined. Results: Among the baseline factors, eGFR and BNP had significant associations with the annual rate of decline in eGFR in Pearson correlation analysis (r = 0.295, p = 0.003; r = 0.223, p = 0.028, respectively). Multiple linear regression analysis also showed the significance of baseline eGFR and BNP as independent predictors of renal function (β = 0.340, p = 0.001; β = 0.278, p = 0.005, respectively). In multivariate logistic regression analysis, eGFR and BNP were independently associated with the risk of a decline in GFR (p = 0.003, p = 0.011, respectively). ROC curve analysis showed a cutoff value of BNP is 17.0 pg/mL for predicting a decline in GFR. Conclusions: The BNP level at baseline is an independent predictor of the annual rate of decline in eGFR. Therefore, monitoring of BNP can play an important role in management of diabetic nephropathy. © 2013 Elsevier Inc. Source


Sakurai Y.,Social Insurance Funabashi Central Hospital | Uchida M.,Social Insurance Funabashi Central Hospital | Mimura F.,Social Insurance Funabashi Central Hospital
Japanese Journal of Anesthesiology | Year: 2014

Background : To test safety and efficacy of ORT (oral rehydration therapy), we compared an ORT group with an intravenous infusion (iv) group by gastric fluid (volume and pH) obtained by endoscope and gastric ultrasonography examination. Methods : Twenty six patients scheduled for endoscopic surgery were assigned to an ORT group or an iv group by standardized clinical path. After gastric ultrasonography examinations to calculate CSA (cross sectional area) of gastric antrum, general anesthesia was induced. Immediately after anesthesia induction, gastric fluid was obtained by endoscopy, and its volume and pH were measured Results : Fifteen and eleven patients were assigned to ORT group and iv group, respectively. In ORT group, CSA was median 1.9 cm2 (95%CI : 1.8-2.6 cm2), gastric volume was median 11 ml (95%CI : 8-18 ml) and pH was median 3.6 (range : 1.2-8.8), and in iv group CSA was median 1.8 cm 2 (95%CI : 1.6-2.7 cm2), gastric volume was median 4 ml (95%CI : 3-12 ml), and pH was median 3.1 (range : 1.2-7.2). There was no significance between the two groups. Conclusions : Gastric volume in ORS group was not smaller compared with that in iv group, and there was no significant difference in pH between the groups. Source

Discover hidden collaborations